Last reviewed · How we verify

NCT05628064

1C70 Feasibility Study

Completed NA Last updated 10 June 2025
What this trial tests

NA trial testing 1C70 in Amputation in 22 participants. Completed in 28 June 2023.

Timeline
24 November 2022
Primary endpoint
30 May 2023
28 June 2023

Quick facts

Lead sponsorOtto Bock Healthcare Products GmbH
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposetreatment
Enrollment22
Start date24 November 2022
Primary completion30 May 2023
Estimated completion28 June 2023
Sites6 locations across Germany

Drugs / interventions tested

Conditions studied

Sponsor

Otto Bock Healthcare Products GmbH

Who can join

18 and older, any sex, with Amputation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to characterize the extent of 1C70 meeting the amputees needs in comparison with their everyday and a comparator foot, in regards of daily activities, mobility and balance, as well as quality of life and pain.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. User preference and patient benefits of a novel energy storing and return foot: A randomized, cross-over clinical trial.
    Maciejasz P, Budny T, Sauer M, Umari M, et al · · 2025 · cited 1× · PMID 39630588 · DOI 10.1097/pxr.0000000000000415

Verify or expand the search:

Other recruiting trials for Amputation

Currently open trials in the same condition.

Other Otto Bock Healthcare Products GmbH trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05628064.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing